Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Avastin. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Bevacizumab (sold as Avastin), first approved Feb 26, 2004, with 15 new uses approved and 0 published complete response letters.
First approved: Feb 26, 2004
Applications: 1
New uses approved: 15
Complete response letters: 0
Medicare spending, 2025: $140M
First approved in the EU: Jan 12, 2005
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
AvastinDrugs with a new dosage indicated for the treatment of ovarian cancer. · Chugai Pharmaceutical Co., Ltd. · Jun 20, 2022
AvastinDrugs with a new indication and a new dosage for the treatment of unresectable hepatocellular carcinoma. · Chugai Pharmaceutical Co., Ltd. · Sep 25, 2020
AvastinDrugs with a new additional indication for the treatment of advanced or recurrent cervical cancer. · Chugai Pharmaceutical Co., Ltd. · May 23, 2016 · Review report
AvastinDrugs with a new additional indication for the treatment of ovarian cancer. · Chugai Pharmaceutical Co., Ltd. · Nov 22, 2013
AvastinDrugs with a new additional indication and a new dosage for the treatment of malignant glioma. · Chugai Pharmaceutical Co., Ltd. · Jun 14, 2013
AvastinDrugs with a new additional indication and a new dosage for the treatment of unresectable or recurrent breast cancer. · Chugai Pharmaceutical Co., Ltd. · Sep 26, 2011
AvastinDrugs with a new additional indication and a new dosage for the treatment of unresectable advanced or recurrent non-squamous non-small cell lung cancer. · Chugai Pharmaceutical Co., Ltd. · Nov 6, 2009
AvastinDrugs with a new additional indication and a new additional dosage and administration for combination therapy with other anticancer drugs (XELOX + BV… · Chugai Pharmaceutical Co., Ltd. · Sep 18, 2009
Clinical Trials
892 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA